High Phosphohistone H3 Expression Correlates with Adverse Clinical, Biological, and Pathological Factors in Neuroblastomas

Overview

Journal J Histochem Cytochem

Publisher Sage Publications

Specialty Biochemistry

Date 2015 Feb 26

PMID 25711230

Citations 5

Authors

Pramila Ramani

Scott Taylor

Elizabeth Miller

Emile Sowa-Avugrah

Margaret T May

Affiliations

Soon will be listed here.

Abstract

Phosphohistone H3 (pHH3), a biomarker of the late G2- and M-phase of the cell cycle, provides a powerful indication of the proliferative state of many cancers. We investigated the prognostic significance of pHH3 by immunostaining 80 neuroblastomas and counting the average number of strongly stained nuclei and mitotic figures. The median and 75th percentile pHH3 proliferation indices (PIs) were 0.54% and 1.06% (range, 0.01% to 2.23%) respectively. pHH3 expression was significantly higher in neuroblastomas from patients with adverse clinical characteristics, all unfavorable pathological factors including high mitosis karyorrhexis index (MKI), and adverse biological factors including MYCN oncogene amplification. High pHH3-PIs, at 1% threshold, were significantly associated with a shorter overall survival (OS) and event-free survival (EFS) in the univariable Cox regression analyses. In the multivariable models, high pHH3 counts were significantly associated with worse OS after adjustment for age but were not independent of either high MKI or MYCN amplification. In children less than 18 months of age, high MKIs and high PHH3-PIs were associated with significantly worse OS and EFS. In conclusion, high pHH3 expression correlates strongly with high MKI and MYCN amplification and indicates poor prognosis in neuroblastomas.

Citing Articles

Potential of Proliferative Markers in Pancreatic Cancer Management: A Systematic Review.

Salahi-Niri A, Zarand P, Mansouri N, Rastgou P, Yazdani O, Esbati R Health Sci Rep. 2025; 8(3):e70412.

PMID: 40051490 PMC: 11882395. DOI: 10.1002/hsr2.70412.

Mitotic Activity in Gastrointestinal Stromal Tumors: Can we use Phosphohistone H3 Immunohistochemistry Instead of Hematoxylin and Eosin for Mitotic Count?.

Sengiz Erhan S, Sensu S, Keser S, Kangal E, Gul A, Alinak Gundogan G Sisli Etfal Hastan Tıp Bul. 2022; 56(2):276-283.

PMID: 35990307 PMC: 9350061. DOI: 10.14744/SEMB.2021.32798.

The Complete Loss of p53 Expression Uniquely Predicts Worse Prognosis in Colorectal Cancer.

Nagao K, Koshino A, Sugimura-Nagata A, Nagano A, Komura M, Ueki A Int J Mol Sci. 2022; 23(6).

PMID: 35328677 PMC: 8948732. DOI: 10.3390/ijms23063252.

PBK Enhances Cellular Proliferation With Histone H3 Phosphorylation and Suppresses Migration and Invasion With CDH1 Stabilization in Colorectal Cancer.

Koshino A, Nagano A, Ota A, Hyodo T, Ueki A, Komura M Front Pharmacol. 2022; 12:772926.

PMID: 35115926 PMC: 8804381. DOI: 10.3389/fphar.2021.772926.

Histone Modifications and Their Targeting in Lymphoid Malignancies.

Fernandez-Serrano M, Winkler R, Santos J, Le Pannerer M, Buschbeck M, Roue G Int J Mol Sci. 2022; 23(1).

PMID: 35008680 PMC: 8745418. DOI: 10.3390/ijms23010253.

References

Goto H, Tomono Y, Ajiro K, Kosako H, Fujita M, Sakurai M . Identification of a novel phosphorylation site on histone H3 coupled with mitotic chromosome condensation. J Biol Chem. 1999; 274(36):25543-9. DOI: 10.1074/jbc.274.36.25543. View

Cohn S, Pearson A, London W, Monclair T, Ambros P, Brodeur G . The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):289-97. PMC: 2650388. DOI: 10.1200/JCO.2008.16.6785. View

Hendzel M, Nishioka W, Raymond Y, Allis C, Bazett-Jones D, Thng J . Chromatin condensation is not associated with apoptosis. J Biol Chem. 1998; 273(38):24470-8. DOI: 10.1074/jbc.273.38.24470. View

Sun A, Zhou W, Lunceford J, Strack P, Dauffenbach L, Kerfoot C . Level of phosphohistone H3 among various types of human cancers. BMJ Open. 2012; 2(5). PMC: 3488750. DOI: 10.1136/bmjopen-2012-001071. View

Gudlaugsson E, Klos J, Skaland I, Janssen E, Smaaland R, Feng W . Prognostic comparison of the proliferation markers (mitotic activity index, phosphohistone H3, Ki67), steroid receptors, HER2, high molecular weight cytokeratins and classical prognostic factors in T₁₋₂N₀M₀ breast cancer. Pol J Pathol. 2013; 64(1):1-8. DOI: 10.5114/pjp.2013.34596. View

Hirota T, Lipp J, Toh B, Peters J . Histone H3 serine 10 phosphorylation by Aurora B causes HP1 dissociation from heterochromatin. Nature. 2005; 438(7071):1176-80. DOI: 10.1038/nature04254. View

Shimada H, Ambros I, Dehner L, Hata J, JOSHI V, Roald B . The International Neuroblastoma Pathology Classification (the Shimada system). Cancer. 1999; 86(2):364-72. View

Maris J, Hogarty M, Bagatell R, Cohn S . Neuroblastoma. Lancet. 2007; 369(9579):2106-20. DOI: 10.1016/S0140-6736(07)60983-0. View

Tetzlaff M, Curry J, Ivan D, Wang W, Torres-Cabala C, Bassett R . Immunodetection of phosphohistone H3 as a surrogate of mitotic figure count and clinical outcome in cutaneous melanoma. Mod Pathol. 2013; 26(9):1153-60. DOI: 10.1038/modpathol.2013.59. View

10.

Crosio C, Fimia G, Loury R, Kimura M, Okano Y, Zhou H . Mitotic phosphorylation of histone H3: spatio-temporal regulation by mammalian Aurora kinases. Mol Cell Biol. 2002; 22(3):874-85. PMC: 133550. DOI: 10.1128/MCB.22.3.874-885.2002. View

11.

Kim Y, Ketter R, Steudel W, Feiden W . Prognostic significance of the mitotic index using the mitosis marker anti-phosphohistone H3 in meningiomas. Am J Clin Pathol. 2007; 128(1):118-25. DOI: 10.1309/HXUNAG34B3CEFDU8. View

12.

Shimada H, Stram D, CHATTEN J, JOSHI V, Hachitanda Y, Brodeur G . Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis. J Natl Cancer Inst. 1995; 87(19):1470-6. DOI: 10.1093/jnci/87.19.1470. View

13.

Nowak M, Svensson M, Carlsson J, Vogel W, Kebschull M, Wernert N . Prognostic significance of phospho-histone H3 in prostate carcinoma. World J Urol. 2013; 32(3):703-7. DOI: 10.1007/s00345-013-1135-y. View

14.

Ladstein R, Bachmann I, Straume O, Akslen L . Prognostic importance of the mitotic marker phosphohistone H3 in cutaneous nodular melanoma. J Invest Dermatol. 2012; 132(4):1247-52. DOI: 10.1038/jid.2011.464. View

15.

Shimada H, CHATTEN J, NEWTON Jr W, Sachs N, Hamoudi A, Chiba T . Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst. 1984; 73(2):405-16. DOI: 10.1093/jnci/73.2.405. View

16.

Gustafson W, Weiss W . Myc proteins as therapeutic targets. Oncogene. 2010; 29(9):1249-59. PMC: 2904682. DOI: 10.1038/onc.2009.512. View

17.

Skaland I, Janssen E, Gudlaugsson E, Klos J, Kjellevold K, Soiland H . Phosphohistone H3 expression has much stronger prognostic value than classical prognosticators in invasive lymph node-negative breast cancer patients less than 55 years of age. Mod Pathol. 2007; 20(12):1307-15. DOI: 10.1038/modpathol.3800972. View

18.

Ambros I, Hata J, Joshi V, Roald B, Dehner L, Tuchler H . Morphologic features of neuroblastoma (Schwannian stroma-poor tumors) in clinically favorable and unfavorable groups. Cancer. 2002; 94(5):1574-83. DOI: 10.1002/cncr.10359. View

19.

Faisal A, Vaughan L, Bavetsias V, Sun C, Atrash B, Avery S . The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo. Mol Cancer Ther. 2011; 10(11):2115-23. PMC: 4298164. DOI: 10.1158/1535-7163.MCT-11-0333. View

20.

Hammond S, Byrum S, Namjoshi S, Graves H, Dennehey B, Tackett A . Mitotic phosphorylation of histone H3 threonine 80. Cell Cycle. 2013; 13(3):440-52. PMC: 3956540. DOI: 10.4161/cc.27269. View